PubRank

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Clinical Trial ID NCT01125566

PubWeight™ 16.55‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01125566

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011 4.12
2 Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol 2016 1.45
3 Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2012 1.23
4 Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 2013 1.19
5 Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 2012 1.12
6 Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta 2014 0.96
7 Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int J Breast Cancer 2012 0.92
8 Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. J Adv Pract Oncol 2015 0.89
9 Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. Breast Cancer (Auckl) 2014 0.87
10 Potential of afatinib in the treatment of patients with HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2012 0.84
11 Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. World J Clin Oncol 2014 0.82
12 The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem 2014 0.80
13 Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer. Curr Breast Cancer Rep 2014 0.79
14 Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. Br J Cancer 2014 0.78
Next 100